1.01

0.98% -0.01

After Hours: 1.06 0.05 +4.95%

Allakos Inc (ALLK)

Overview News Price History Option Chain Discussions Forecast

Allakos Inc stock is currently priced at $1.01, with a 24-hour trading volume of 381.48K. It has seen a -0.98% decreased in the last 24 hours and a -23.48% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.05 pivot point. If it approaches the $0.9933 support level, significant changes may occur.

Previous Close:

$1.02

Open:

$1.01

24h Volume:

381.48K

Market Cap:

$89.43M

Revenue:

Net Income/Loss:

$-166.14M

P/E Ratio:

-0.5233

EPS:

-1.93

Net Cash Flow:

$-139.92M

1W Performance:

-4.72%

1M Performance:

-23.48%

6M Performance:

-44.81%

1Y Performance:

-76.29%

1D Range:

$0.9799

$1.045

52W Range:

$0.9799

$5.64

Allakos Inc Stock (ALLK) Company Profile

Name

Allakos Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

650-597-5002

Address

75 Shoreway Road, Suite A, San Carlos, CA

Employee

Twitter

Next Earnings Date

2024-05-24

Latest SEC Filings

ALLK's Discussions on Twitter

Allakos Inc Stock (ALLK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-12-23	Upgrade	Jefferies	Hold → Buy
Mar-07-23	Initiated	Piper Sandler	Overweight
Sep-12-22	Downgrade	SMBC Nikko	Neutral → Underperform
Dec-22-21	Downgrade	BofA Securities	Buy → Underperform
Dec-22-21	Downgrade	Cowen	Outperform → Market Perform
Dec-22-21	Downgrade	Jefferies	Buy → Hold
Dec-22-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-22-21	Downgrade	William Blair	Outperform → Mkt Perform
Aug-26-21	Initiated	Morgan Stanley	Equal-Weight
Jul-15-21	Initiated	Cowen	Outperform
May-18-21	Initiated	H.C. Wainwright	Buy
Feb-24-21	Initiated	Cantor Fitzgerald	Overweight
Jan-15-21	Initiated	BofA Securities	Buy
Dec-21-20	Initiated	SVB Leerink	Outperform
Feb-27-20	Initiated	Barclays	Underweight
Feb-04-20	Resumed	Goldman	Neutral
Aug-13-18	Initiated	Goldman	Neutral
Aug-13-18	Initiated	Jefferies	Buy
Aug-13-18	Initiated	William Blair	Outperform

View All

Allakos Inc Stock (ALLK) Latest News

Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions

Zacks Investment Research

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

GlobeNewswire Inc.

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

GlobeNewswire Inc.

Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update

Zacks Investment Research

Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug

Zacks Investment Research

Allakos Inc Stock (ALLK) Financials Data

Allakos Inc (ALLK) Net Income 2024

ALLK net income (TTM) was -$166.14 million for the quarter ending September 30, 2023, a +55.26% increase year-over-year.

Allakos Inc (ALLK) Cash Flow 2024

ALLK recorded a free cash flow (TTM) of -$139.91 million for the quarter ending September 30, 2023, a +56.55% increase year-over-year.

Allakos Inc (ALLK) Earnings per Share 2024

ALLK earnings per share (TTM) was -$1.92 for the quarter ending September 30, 2023, a +71.60% growth year-over-year.

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.